Biostage (OTCMKTS:BSTG) issued its earnings results on Tuesday. The company reported ($0.33) EPS for the quarter, Bloomberg Earnings reports.
Biostage stock opened at $2.35 on Friday. The company has a current ratio of 2.28, a quick ratio of 2.28 and a debt-to-equity ratio of 0.01. The stock has a fifty day moving average price of $2.38 and a two-hundred day moving average price of $2.42. Biostage has a 52-week low of $0.75 and a 52-week high of $3.30.
Separately, ValuEngine upgraded Biostage from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd.
Biostage, Inc, a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. It is developing bioengineered organ implants, which addresses the damage of the esophagus, bronchus, and trachea due to cancer, infection, trauma, or congenital abnormalities.
Receive News & Ratings for Biostage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biostage and related companies with MarketBeat.com's FREE daily email newsletter.